Form 4: Akero Therapeutics Director Sells Shares Post-Novo Nordisk Merger

Akero Therapeutics director Jane Henderson disposed of all her beneficial ownership in the company following its merger with Novo Nordisk, receiving cash and contingent value rights for her equity.

Summary

• Reporting Person Jane Henderson, a Director of Akero Therapeutics, Inc. (AKRO), disposed of all her beneficial ownership in the company.
• The disposition occurred on December 9, 2025, as a result of the merger of Akero Therapeutics with NN Invest Sub, Inc., a subsidiary of Novo Nordisk A/S.
• Akero Therapeutics is now a wholly-owned subsidiary of Novo Nordisk A/S.
• Ms. Henderson's 9,398 restricted stock units (RSUs) were fully vested, cancelled, and converted into a right to receive $54.00 in cash (Closing Consideration) and one Contingent Value Right (CVR) for $6.00 per RSU, contingent on a specified milestone.
• Her compensatory stock options, totaling 93,797 shares across various exercise prices, were also fully vested, cancelled, and converted into a cash payment equal to the excess of the $54.00 Closing Consideration over the option's exercise price, multiplied by the number of shares, plus one CVR per share.

Sentiment

Score: 8

Explanation: The filing reports the successful completion of a merger and the monetization of equity holdings for a director, including a fixed cash component and a contingent upside, which is a positive outcome for the insider and reflects a successful acquisition for the company.

Positives

• The Reporting Person received cash and CVRs for all her equity holdings, indicating a successful monetization of her investment.
• The merger resulted in a fixed cash payment of $54.00 per share for RSUs and options (above exercise price), plus potential additional value from CVRs.
• The company's acquisition by Novo Nordisk A/S represents a significant strategic event, potentially validating its assets and pipeline.

Negatives

• The contingent value right (CVR) component of the consideration is not guaranteed and depends on the achievement of a specified milestone.
• The company's independent public trading ceased, removing direct public market investment opportunities in Akero Therapeutics.

Risks

• The $6.00 per CVR payment is contingent upon the achievement of a specified milestone, meaning the full potential value of the CVRs may not be realized.

Future Outlook

The future outlook for Akero Therapeutics is as a wholly-owned subsidiary of Novo Nordisk A/S. The realization of the $6.00 CVR payment is contingent on a specified future milestone being achieved.

Industry Context

This transaction reflects a trend of larger pharmaceutical companies acquiring promising biotechnology firms to bolster their pipelines and expand market reach. Novo Nordisk's acquisition of Akero Therapeutics indicates a strategic interest in Akero's therapeutic areas, likely related to metabolic diseases or other specialties where Novo Nordisk has a strong presence.

Stakeholder Impact

• Shareholders of Akero Therapeutics received cash and CVRs for their shares as part of the merger consideration.
• Employees with similar equity compensation (RSUs, options) would also have their holdings converted into cash and CVRs.

Next Steps

• Achievement of the specified milestone for the Contingent Value Rights (CVRs) to trigger the additional $6.00 cash payment.

Key Dates

Keywords

Akero Therapeutics, AKRO, Novo Nordisk, Merger, Acquisition, Form 4, Insider Trading, Beneficial Ownership, Restricted Stock Units, Stock Options, Contingent Value Right, CVR, Biotechnology, Pharmaceuticals